Stefan Grass
Net worth: 66 695 $ as of 2024-03-30
Profile
Stefan Grass worked as a Medical Officer at CSL Behring AB.
He also served as the Chief Medical & Technology Officer at Bactiguard Holding AB from 2019 to 2020.
Dr. Grass obtained his graduate and doctorate degrees from Karolinska Institutet.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BACTIGUARD HOLDING AB
0.03% | 2022-12-30 | 9,850 ( 0.03% ) | 66 695 $ | 2024-03-30 |
Former positions of Stefan Grass
| Companies | Position | End |
|---|---|---|
CSL Behring AB
 CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Corporate Officer/Principal | - |
| BACTIGUARD HOLDING AB | Chief Tech/Sci/R&D Officer | - |
Training of Stefan Grass
| Karolinska Institutet | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| BACTIGUARD HOLDING AB | Health Technology |
| Private companies | 1 |
|---|---|
CSL Behring AB
CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Health Technology |
- Stock Market
- Insiders
- Stefan Grass
